Pfizer CDR (CAD Hedged)
- Country
- Ownership
- -
- Employees
- 88K
- Market Cap
- -
- Introduction
Pfizer Inc. is a research-based global biopharmaceutical company, which engages in the discovery, development, manufacture, marketing, sales and distribution of biopharmaceutical products worldwide. The firm works across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases. The company was founded by Charles Pfizer Sr. and Charles Erhart in 1849 and is headquartered in New York, NY.
Clinical Trials
255
Trial Phases
5 Phases
Drug Approvals
24
Drug Approvals
Glipizide Extended Release Tablets
- Product Name
- 瑞易宁
- Approval Number
- 国药准字HJ20160140
- Approval Date
- Oct 14, 2024
Glipizide Extended Release Tablets
- Product Name
- 瑞易宁
- Approval Number
- 国药准字HJ20150361
- Approval Date
- Oct 14, 2024
Glipizide Extended Release Tablets
- Product Name
- 瑞易宁
- Approval Number
- 国药准字HJ20160139
- Approval Date
- Oct 14, 2024
Glipizide Extended Release Tablets
- Product Name
- 瑞易宁
- Approval Number
- 国药准字HJ20150360
- Approval Date
- Oct 14, 2024
Carboprost Tromethamine Injection
- Product Name
- 欣母沛
- Approval Number
- 国药准字HJ20170146
- Approval Date
- Feb 22, 2022
Linezolid for Oral Suspension
- Product Name
- 斯沃
- Approval Number
- 国药准字HJ20170247
- Approval Date
- Sep 2, 2021
Clinical Trials
Distribution across different clinical trial phases (182 trials with phase data)• Click on a phase to view related trials
News
RESTEM Receives FDA Orphan Drug Designation for Stem Cell Therapy in Polymyositis Treatment
RESTEM, a clinical-stage biotech company, received FDA Orphan Drug Designation in December 2024 for its umbilical cord outer lining stem cell program targeting polymyositis and dermatomyositis.
Pfizer's Padcev-Keytruda Combination Shows Significant Survival Benefit in Muscle-Invasive Bladder Cancer Trial
Pfizer's Padcev combined with Merck's Keytruda significantly improved event-free survival and overall survival in muscle-invasive bladder cancer patients when administered before and after surgery compared to surgery alone.
New Market Report Reveals Global Mycosis Fungoides Clinical Trial Landscape with Major Pharma Players
A comprehensive 2025 market report analyzes the global clinical trial landscape for mycosis fungoides, providing insights into trial distribution across regions and phases.
Major Pharmaceutical Companies Lead Global Renal Failure Clinical Trials Landscape in 2025
A comprehensive 2025 clinical trials report reveals the global landscape of renal failure research, featuring data from over 80 clinical trial registries worldwide.
Global Clinical Trials Landscape for Alopecia Universalis Reveals Growing Research Activity Across Major Pharmaceutical Companies
A comprehensive 2025 clinical trials review reveals the current global research landscape for alopecia universalis, analyzing trial distribution across regions, phases, and sponsor types.
Hengrui Pharmaceutical Secures NMPA Approval for JAK1 Inhibitor Ivarmacitinib in Severe Alopecia Areata
Hengrui Pharmaceutical received NMPA approval for Ivarmacitinib Sulfate Tablets, a second-generation JAK1 inhibitor, for treating severe alopecia areata in China.
ANGLE Advances Liquid Biopsy Technology with Dual DNA Analysis and Androgen Receptor Profiling at EACR 2025
ANGLE presented breakthrough data at EACR 2025 demonstrating DNA dual analysis combining CTC-DNA and ctDNA from single blood samples, revealing 53% of mutations found exclusively in CTCs in lung cancer patients.
QureBio Secures $14 Million Series C1 Funding to Advance Bispecific Antibody Pipeline
QureBio completed a Series C1 financing round raising nearly CNY 100 million (approximately USD 14 million) led by Efung Capital to accelerate clinical trials of its novel antibody therapeutics.
Global GVHD Clinical Trials Review Reveals Key Trends and Strategic Opportunities for 2025
A comprehensive analysis of the global Graft Versus Host Disease clinical trial landscape shows significant activity across G7 and E7 countries, offering strategic insights for pharmaceutical companies.
Global Friedreich Ataxia Clinical Trials Landscape Analyzed in New Report
A new report provides a comprehensive overview of Friedreich Ataxia clinical trials, offering insights into trial numbers and enrollment trends globally.